Ginkgo Bioworks Holdings (DNA) Gross Margin (2020 - 2026)
Ginkgo Bioworks Holdings' (DNA) quarterly Gross Margin came in at 84.09% in Q1 2026, down 521.0% YoY from 19.97% in Q1 2025, and up 93.96% on a QoQ basis from 43.36% in Q4 2025.
Ginkgo Bioworks Holdings (DNA) Gross Margin (2020 - 2026) Analysis & Trends
Ginkgo Bioworks Holdings (DNA) has 7 years of Gross Margin data on file, last reported at 84.09% in Q1 2026.
- Quarterly Gross Margin fell 521.0% year-over-year to 84.09% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 74.83% (down 2073.0% YoY) and the FY2025 annual result came in at 83.02%, down 1434.0% from the prior year.
- Gross Margin improved to 84.09% in Q1 2026, from 43.36% in the prior quarter.
- In the past five years, Gross Margin ranged from a high of 256.03% in Q4 2022 to a low of 43.36% in Q4 2025.
- A 5-year average of 96.2% and a median of 89.3% in 2025 frame the typical range for Gross Margin.
- Annual changes were most pronounced in 2022 — Gross Margin soared 15928 bps — and 2023, when it tumbled 15295 bps.
- Tracing DNA's Gross Margin over 5 years: stood at 256.03% in 2022, then slumped by 60 bps to 103.08% in 2023, then declined by 8 bps to 95.28% in 2024, then tumbled by 54 bps to 43.36% in 2025, then soared by 94 bps to 84.09% in 2026.
- The last three Gross Margin figures came in at 84.09% (Q1 2026), 43.36% (Q4 2025), and 78.95% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 90.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 89.76% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 60,631,834.75% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 76.90% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 84.20% |
| 10 | Ginkgo Bioworks Holdings | 432.60 Mn | 348.06 Mn | 18.44 Mn | 91.47% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 91.47% |
| Mar 31, 2026 | 84.09% |
| Dec 31, 2025 | 43.36% |
| Sep 30, 2025 | 78.95% |
| Jun 30, 2025 | 89.15% |
| Mar 31, 2025 | 89.30% |
| Dec 31, 2024 | 95.28% |
| Sep 30, 2024 | 97.74% |
| Jun 30, 2024 | 96.59% |
| Mar 31, 2024 | 100.00% |
| Dec 31, 2023 | 103.08% |
| Sep 30, 2023 | 87.51% |
| Jun 30, 2023 | 80.06% |
| Mar 31, 2023 | 77.90% |
| Dec 31, 2022 | 256.03% |
| Sep 30, 2022 | 62.87% |
| Jun 30, 2022 | 98.31% |
| Mar 31, 2022 | 95.19% |
| Dec 31, 2021 | 96.75% |
| Sep 30, 2021 | 75.68% |